239 related articles for article (PubMed ID: 25156795)
1. Sustained favourable HIV viral load response in South African patients during concomitant HAART and cancer therapy.
Musyoki AM; Msibi TL; Motswaledi MH; Selabe SG; Mphahlele MJ
J Med Virol; 2015 Feb; 87(2):192-8. PubMed ID: 25156795
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Predicting the magnitude of short-term CD4+ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy.
Castagna A; Galli L; Torti C; D'Arminio Monforte A; Mussini C; Antinori A; Cozzi-Lepri A; Ladisa N; De Luca A; Seminari E; Gianotti N; Lazzarin A
Antivir Ther; 2010; 15(2):165-75. PubMed ID: 20386071
[TBL] [Abstract][Full Text] [Related]
4. Active co-infection with HBV and/or HCV in South African HIV positive patients due for cancer therapy.
Musyoki AM; Msibi TL; Motswaledi MH; Selabe SG; Monokoane TS; Mphahlele MJ
J Med Virol; 2015 Feb; 87(2):213-21. PubMed ID: 25156907
[TBL] [Abstract][Full Text] [Related]
5. Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study.
Omland LH; Weis N; Skinhøj P; Laursen A; Christensen PB; Nielsen HI; Møller A; Engsig F; Sørensen HT; Obel N
HIV Med; 2008 May; 9(5):300-6. PubMed ID: 18400077
[TBL] [Abstract][Full Text] [Related]
6. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
[TBL] [Abstract][Full Text] [Related]
7. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
8. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection.
Asmuth DM; Busch MP; Laycock ME; Mohr BA; Kalish LA; van der Horst CM;
Antiviral Res; 2004 Aug; 63(2):123-31. PubMed ID: 15302141
[TBL] [Abstract][Full Text] [Related]
10. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and impact of hepatitis B and C virus co-infections in antiretroviral treatment naïve patients with HIV infection at a major treatment center in Ghana.
Sagoe KW; Agyei AA; Ziga F; Lartey M; Adiku TK; Seshi M; Arens MQ; Mingle JA
J Med Virol; 2012 Jan; 84(1):6-10. PubMed ID: 22095533
[TBL] [Abstract][Full Text] [Related]
12. Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa.
Seyler C; Adjé-Touré C; Messou E; Dakoury-Dogbo N; Rouet F; Gabillard D; Nolan M; Toure S; Anglaret X
AIDS; 2007 May; 21(9):1157-64. PubMed ID: 17502726
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal study in HIV/HCV-coinfected HAART-naive patients and role of HCV genotype.
Caudai C; Pianese M; Zacchini F; Toti M; Zazzi M; Valensin PE
J Clin Virol; 2005 Feb; 32(2):151-5. PubMed ID: 15653418
[TBL] [Abstract][Full Text] [Related]
14. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI
J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397
[TBL] [Abstract][Full Text] [Related]
15. Role of antiretroviral therapies in mucocutaneous manifestations in HIV-infected children over a period of two decades.
Seoane Reula E; Bellon JM; Gurbindo D; Muñoz-Fernandez MA
Br J Dermatol; 2005 Aug; 153(2):382-9. PubMed ID: 16086754
[TBL] [Abstract][Full Text] [Related]
16. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy.
Yang JJ; Tsai MS; Sun HY; Hsieh SM; Chen MY; Sheng WH; Chang SC
J Microbiol Immunol Infect; 2015 Apr; 48(2):130-6. PubMed ID: 24064287
[TBL] [Abstract][Full Text] [Related]
17. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
18. Immunological and virological response to haart in HIV-1 patients co-infected with hepatitis B and C viruses.
Okwuraiwe AP; Audu RA; Salu OB; Onwuamah CK; Amoo OS; Ige FA; Meshack EH; Jamda PD; Odunukwe NN; Onwujekwe DI; Ezechi OC; Idigbe EO
West Afr J Med; 2012; 31(2):124-8. PubMed ID: 23208483
[TBL] [Abstract][Full Text] [Related]
19. Dysregulation of CD28 and CTLA-4 expression by CD4 T cells from previously immunodeficient HIV-infected patients with sustained virological responses to highly active antiretroviral therapy.
Stone SF; Price P; French MA
HIV Med; 2005 Jul; 6(4):278-83. PubMed ID: 16011533
[TBL] [Abstract][Full Text] [Related]
20. Normalized CD8+ but not CD4+ lymphocyte IL-2 expression is associated with early treatment with highly active antiretroviral therapy.
Akerele T; Galatowicz G; Bunce C; Calder V; Lynn WA; Lightman S
Clin Immunol; 2006 Nov; 121(2):191-7. PubMed ID: 16987710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
